Axa
BIO icon

Axa’s Bio-Rad Laboratories Class A BIO Stock Holding History

Axa’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,200
Closed -$4.64M – 1233
2021
Q2 		$4.64M Buy
7,200
+6,500
+929% +$3.96M 0.01% 726
2021
Q1 		$400K Buy
+700
New +$415K ﹤0.01% 1101
2020
Q4 		– Sell
-1,000
Closed -$515K – 1265
2020
Q3 		$515K Sell
1,000
-400
-29% -$203K ﹤0.01% 1033
2020
Q2 		$632K Sell
1,400
-6,900
-83% -$3.04M ﹤0.01% 1026
2020
Q1 		$2.91M Buy
+8,300
New +$3.05M 0.01% 657
2015
Q2 		– Sell
-36,300
Closed -$4.91M – 1404
2015
Q1 		$4.91M Buy
36,300
+6,600
+22% +$818K 0.02% 608
2014
Q4 		$3.58M Buy
29,700
+25,100
+546% +$2.89M 0.01% 644
2014
Q3 		$521K Buy
+4,600
New +$545K ﹤0.01% 1055
2013
Q3 		– Sell
-2,100
Closed -$236K – 1283
2013
Q2 		$236K Buy
+2,100
New +$246K ﹤0.01% 1089

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Axa's BIO Position: Q3 2021 in Review

Axa sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2021, closing a stake of 7,200 shares — an estimated $4.64M sold.

Axa first reported a position in BIO in Q2 2013 and held it in 9 quarters. The position peaked at $4.91M in Q1 2015. 508 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • Axa reported no remaining Bio-Rad Laboratories Class A position as of Q3 2021 after selling out during the quarter.
  • Axa sold 7,200 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $4.64M.
  • Axa first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 9 quarters.
  • Axa's Bio-Rad Laboratories Class A position peaked at $4.91M in Q1 2015.
  • 508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.